A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Phase of Trial: Phase III
Latest Information Update: 02 Apr 2018
At a glance
- Drugs Savolitinib (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms SAVOIR
- Sponsors AstraZeneca
- 12 Sep 2017 Trial design of the study presented at the 42nd European Society for Medical Oncology Congress.
- 11 Aug 2017 Planned End Date changed from 19 Feb 2021 to 30 Jun 2021.
- 11 Aug 2017 Planned primary completion date changed from 19 Feb 2021 to 31 Mar 2020.